FFO
BIO icon

Fortitude Family Office’s Bio-Rad Laboratories Class A BIO Stock Holding History

Fortitude Family Office’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.8K Buy
34
+2
+6% +$698 ﹤0.01% 1088
2026
Q2 		$9.4K Buy
32
+4
+14% +$1.14K ﹤0.01% 799
2026
Q1 		$7.8K Buy
28
+5
+22% +$1.44K ﹤0.01% 745
2025
Q4 		$6.97K Buy
23
+1
+5% +$312 ﹤0.01% 698
2025
Q3 		$6.17K Buy
22
+10
+83% +$2.72K ﹤0.01% 741
2025
Q2 		$2.9K Sell
12
-4
-25% -$946 ﹤0.01% 1026
2025
Q1 		$3.9K Sell
16
-2
-11% -$602 ﹤0.01% 791
2024
Q4 		$5.91K Sell
18
-2
-10% -$679 ﹤0.01% 788
2024
Q3 		$6.69K Buy
20
+4
+25% +$1.27K ﹤0.01% 686
2024
Q2 		$4.37K Hold
16
– – ﹤0.01% 644
2024
Q1 		$5.53K Hold
16
– – ﹤0.01% 558
2023
Q4 		$5.17K Buy
+16
New +$5.01K ﹤0.01% 614

Other funds holding BIO

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return
Gateway Investment Advisers
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office's BIO Position: Q3 2026 in Review

Fortitude Family Office increased its Bio-Rad Laboratories Class A (BIO) stake by 6.3% in Q3 2026, buying an estimated $698 and bringing the position to 34 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1088.

Fortitude Family Office first reported a position in BIO in Q4 2023 and has held it in 12 quarters since. 33 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • Fortitude Family Office held 34 shares of Bio-Rad Laboratories Class A worth $12.8K as of Q3 2026.
  • Fortitude Family Office bought 2 Bio-Rad Laboratories Class A shares in Q3 2026, an estimated $698.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1088 holding.
  • Fortitude Family Office first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and has held it in 12 quarters since.
  • 33 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.